ObsEva SA: Up on positive data from preterm labor treatment study
16/11/2020 11:47
** U.S. shares of Switzerland-based women's drug developer
OBSV.O up 16% at $2.40 premarket, their highest in a month
** OBSV reports positive top-line results from its mid-stage
study of its experimental drug ebopiprant for treating preterm
labor urn:newsml:reuters.com:*:nGNE2lFWNz
** Says ebopiprant reduced delivery in singleton pregnancies
by 55% when used in combination with another drug compared to
the other drug alone urn:newsml:reuters.com:*:nGNE2lFWNz
** Follow-up of infants at 6, 12 and 24 months after birth
is continuing and results will be available in 2021 and 2022 -
OBSV
** Up to Friday's close, stock down 45.8% YTD
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))
Recent news on Obseva SA
See all newsBrief: Obseva Announces Wind-Down Of Operations And Likely Not Going To Be Able To Satisfy Requirements For Maintaining Its Listing
Brief: Obseva Applies For Moratorium To Facilitate Pivotal Deals
Brief: Obseva SA Says Xoma Will Receive Full Worldwide Rights On Ebopiprant Following Termination Of License Agreement With Organon
Brief: Obseva Appoints Fabien De Ladonchamps As Chief Executive Officer Effective May 1, 2023
Brief: Obseva Announces Change Of Central Securities Depositary